Novel Prostate Cancer Immunotherapies (BIDMC 1187)

Category:    Therapeutics - Drugs

KeyWords:  Cancer;  Peptide;  Vaccine;  

BIDMC ID:    1187

Abstract:

Effective tumor specific immunotherapies for the treatment and prevention of prostate cancer using: Vaccines composed of novel peptides Immune activated T cells Background: Prostate cancer immunotherapies (cell-based treatments, vaccines, antibodies) have been unsuccessful largely due to a lack of a causative oncogene antigen target and to an inability to overcome immune tolerance to the targeted tumor antigen. BIDMC investigators have potentially overcome these obstacles to an effective immunotherapy with their discovery of immunodominant peptides from two prostate tumor-associated proteins: transcription factors ERG and SIM2. These new targets are ideal candidates for immunotherapy because these proteins are not significantly present in normal human adult cells, but are over-expressed in 90-100% (for SIM2) 40-60% (for ERG) of human prostatectomy specimens.

Inventor:   Martin Sanda, MD Mohamed S. Arredouani, PhD

Commercial Opportunity:

Development of vaccines and cellular immunotherapies alone or in combination with existing treatments such as androgen deprivation.

Competitive Advantages:

Prostate Tumor Specificity Ability to Overcome Immune Tolerance to a Tumor Antigen

Related Publications:

NCI Translates Meeting, November 2008
Manuscript in preparation

State of Development:

In vivo studies demonstrate that both ERG and SIM2 peptides produce immunogenicity.    

Next step: Validation in prostate
cancer animal models and  clinical trials

Related Technology URL:

http://research.bidmc.harvard.edu/research/ResearchPIInfo.ASP?Submit=Display&PersonID=14127&NoFrame=Yes

Patent Status:

US Provisional Patent Filed
Opportunities for Licensing Available

TVO Contact Info:
     Catherine M Lenich
     Senior Associate TVO
     clenich@bidmc.harvard.edu
     Phone: 617-667-0568   Fax: 617-667-0646

     Beth Israel Deaconess Medical Center
     Technology Ventures Office  Room: BR-0200
     330 Brookline Avenue
     Boston, MA 02215